Internal Medicine, Gastroenterology · Fountain Valley, CA
NPI
1649570268
Since 2010
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
4
Medicare group memberships
Hospitals
2
Hospital affiliations
18035 Brookhurst St Ste 2100
Fountain Valley, CA, 92708
Phone (657) 241-9090
Groups this clinician bills Medicare through
Medicare paid, 2024
$12K
103 services
Medicare patients, 2024
59
Average age 71
Drug cost, 2024
$648K
1,087 prescriptions
Company payments, 2025
$741
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vincent W Kao was code 99214 (office e&m - established), 27 times for 17 patients. In total Vincent W Kao billed 103 services in 16 codes, and Medicare paid $12K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-05-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 27 | 17 | $99.11 | $2,676 |
| 99204 Office E&M - New | Office | 17 | 17 | $111.55 | $1,896 |
| 99203 Office E&M - New | Office | 14 | 14 | $63.05 | $883 |
| 45380 Lower GI Endoscopy - Other | Facility | 11 | 11 | $142.55 | $1,568 |
By year: 2022 $12K for 107 services; 2023 $17K for 140 services; 2024 $12K for 103 services.
Medicare prescription drug claims, 2024
In 2024, the drug Vincent W Kao prescribed most often to Medicare patients was Sod Sulf-Potass Sulf-Mag Sulf (Sodium, Potassium,mag Sulfates), with 259 prescriptions and refills. In total Vincent W Kao wrote 1,087 Medicare prescriptions that cost $648K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 259 | 259 | 247 | $14K |
| Omeprazole Generic | 209 | 521 | 72 | $2,986 |
| Pantoprazole Sodium Generic | 102 | 271 | 42 | $1,850 |
| Linzess Linaclotide | 78 | 118 | 30 | $60K |
| Famotidine Generic | 46 | 123 | 20 | $893 |
| Dicyclomine Hcl Generic | 45 | 47 | 16 | $433 |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 35 | 35 | 35 | $435 |
| Lactulose Generic | 24 | 26 | Under 11 | $607 |
| Ondansetron Hcl Generic | 22 | 22 | Under 11 | $106 |
| Constulose Lactulose | 18 | 18 | Under 11 | $1,323 |
| Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl | 16 | 16 | 16 | $207 |
| Entyvio Pen Vedolizumab | 13 | 15 | Under 11 | $95K |
| Ondansetron Odt Ondansetron | 13 | 17 | Under 11 | $504 |
| Humira(Cf) Pen Adalimumab | 12 | 21 | Under 11 | $143K |
Brand drugs: 204 claims; generic drugs: 883 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vincent W Kao $741 ($741 in general payments such as food, travel and fees) from 6 companies. The largest payer was Abbvie Inc. with $284.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.